Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies.

In 30 seconds

This systematic review examined toxicity outcomes and mitigation strategies in phase III trials comparing radiotherapy fractionation schedules for prostate cancer, including at least one hypofractionated arm. Thirty-two articles were included. Late grade≥2 genitourinary toxicity ranged from 12-46% with isodose and 15-45% with dose-escalated moderately hypofractionated radiotherapy. The review also found a grade≥2 genitourinary toxicity flare 12 to 24 months after stereotactic body radiotherapy, with higher cumulative incidence at 5 years. Motion management with margin reduction was associated with halved grade≥2 toxicity rates after stereotactic body radiotherapy.

Key findings

• Late grade≥2 genitourinary toxicity ranged from 12-46% with isodose and 15-45% with dose-escalated moderately hypofractionated radiotherapy.
• After stereotactic body radiotherapy, grade≥2 genitourinary toxicity flared 12 to 24 months later, contributing to higher cumulative incidence at 5 years.
• Higher baseline IPSS was suggested to predict late grade≥2 genitourinary toxicity after both moderately hypofractionated radiotherapy and stereotactic body radiotherapy.
• Motion management and margin reduction halved grade≥2 toxicity rates following prostate cancer stereotactic body radiotherapy.

Why it matters

Hypofractionated schedules can intensify treatment while late genitourinary toxicity remains frequent. The review highlights the importance of considering baseline urinary symptoms and of reducing dose to adjacent organs at risk. Its findings also draw attention to toxicity that may emerge beyond the early post-treatment period, supporting careful assessment of longer-term outcomes.

What to keep in mind

The review included phase III trials with differing fractionation schedules and toxicity outcomes, limiting direct comparison across reported ranges.